BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYMFENTRA (infliximab-dyyb) is a biosimilar monoclonal antibody that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is approved for six inflammatory indications: rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. As a TNF inhibitor, it reduces inflammation and immune-mediated tissue damage across these autoimmune and inflammatory bowel conditions.
Growth
Early-stage biosimilar with growth potential; expect expanding commercial team as market penetration accelerates and formulary positioning solidifies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Started Nov 2025
200 enrolled
Ulcerative Colitis (UC)Crohn's Disease (CD)Indeterminate Colitis+1 more
Career Relevance
ZYMFENTRA offers entry or mid-career growth opportunities in biosimilar commercialization, a high-velocity segment with focus on payer negotiations, formulary placement, and market share capture from reference products. Roles emphasize access strategy and health economics over clinical development, making this ideal for professionals with payer/managed care experience or those seeking commercial intensity.
Brand Manager
Worked on ZYMFENTRA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.